Request Appointment
12902 Usf Magnolia DrTampa, FL 33612
Overview of Dr. Sallman
Dr. David Sallman is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of South Florida College of Medicine and has been in practice 7 years. He is one of 197 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2013 - 2016
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2010 - 2013- University of South Florida College of MedicineClass of 2010
Certifications & Licensure
FL State Medical License 2013 - 2027
MA State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Junior Faculty Research Award for Clinical Science 2020
- CMS Meaningful Use Stage Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2017
- CMS Meaningful Use Stage Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2017
Clinical Trials
- Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Start of enrollment: 2017 May 18
- DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Start of enrollment: 2018 Sep 18
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome Start of enrollment: 2018 Dec 14
Publications & Presentations
PubMed
- Impact of autoimmune diseases or inflammatory manifestations on response and outcome in high-risk myelodysplastic syndromes and chronic myelomonocytic leukemia.Rinzine Sammut, Antoine Benichou, Chen Wang, Michael Loschi, Sami Benachour
Leukemia Research. 2026-01-16 - Menin inhibitors for adult acute myeloid leukemia: 2025 update.Umar Iqbal, Julia Fadul, David A Sallman, Rory M Shallis
Expert Opinion on Investigational Drugs. 2026-01-06 - Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study.Irfan Yasin, Anna Stengel, Haipeng Shao, Amandeep Kaur, Emily F Mason
Cancer. 2026-01-01
Abstracts/Posters
- A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti_Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocyti...David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical StateDavid A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess BlastsDavid A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.2019 ASCO Annual Meeting - 6/1/2019
- Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Addressing Frequency of Care to Improve Quality of Life in Patients with Low-Risk AnemiaJuly 25th, 2024- Magrolimab plus Azacitidine Results in Promising Activity in Higher-Risk MDS PatientsMarch 9th, 2023
- First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic SyndromesDecember 9th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
